Genesis Therapeutics

Genesis Therapeutics is a biotech leader in molecular AI that unites deep learning and physics-based machine learning in its proprietary GEMS platform and Pearl foundation model to unlock tough protein targets and rapidly discover highly potent, selective small-molecule therapeutics across multiple disease areas. With state-of-the-art protein–ligand prediction, industry-leading speed, and a growing pipeline, Genesis partners with pharma while advancing its own AI-enabled medicines.

Genesis Therapeutics is a biotech leader in molecular AI that unites deep learning and physics-based machine learning in its proprietary GEMS platform and Pearl foundation model to unlock tough protein targets and rapidly discover highly potent, selective small-molecule therapeutics across multiple disease areas. With state-of-the-art protein–ligand prediction, industry-leading speed, and a growing pipeline, Genesis partners with pharma while advancing its own AI-enabled medicines. The company has secured over $256M in funding from top investors including a16z, Fidelity, BlackRock, and NVIDIA, and established major collaborations with Gilead and Incyte (including a $120M upfront expansion).